secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2022-05-31T23:59:59+00:00
Accession:  0001140361-22-021148
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brooklyn ImmunoTherapeutics appoints interim CEO Matt Angel, CFO Andrew Jackson; CEO Federoff resigns
--------------------------------------------------------------------------------

- CEO Howard Federoff resigned effective May 26, 2022; received $225K bonus, $450K salary continuation, and accelerated stock options covering 1,420,095 shares.
- Matt Angel, co-founder of Factor Bioscience, appointed interim President and CEO; Factor was a Novellus acquisition counterparty that received $1.7M cash and ~2.58M shares.
- Andrew Jackson named CFO; receives $415K base salary, 40% target bonus, and a stock option grant for 664,800 shares.
- Four directors (Heather Redman, Erich Mohr, Erin Enright, Dennis Langer) will not stand for reelection at postponed annual meeting.
- 2022 annual meeting postponed to a later date; new proxy statement expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/0001140361-22-021148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036122021148/brhc10038309_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-021148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer